Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Onconova Therapeutics, Inc.

  • Steven Fruchtman, Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways. Advanced clinical trials with Rigosertib are aimed at the unmet medical needs of patients with MDS. There has not been an FDA-approved treatment for higher-risk MDS in over a decade. Both IV and oral rigosertib are protected by issued patents worldwide (earliest expiry 2026) and have been granted orphan drug designation for MDS in the US, Europe, and Japan. Very promising data from the Phase 2 combination trial of o

  • Date:Monday, February 11
  • Time:1:15 PM - 1:30 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23519
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Investor awareness
  • Company Website:www.onconova.com
  • Company HQ City:Newtown
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Ticker:ONTX
  • Exchange:Nasdaq
  • CEO/Top Company Official:Steven M. Fruchtman, MD
  • Year Founded:1998
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Rigosertib
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Speakers
Steven Fruchtman
Onconova Therapeutics, Inc.
Back